Redeye initiates coverage of Mentice, a medtech company expanding its TAM many times over through vertical integration from endovascular simulation to IGIT performance solutions. We judge today’s share price represents an attractive entry opportunity for long-term-oriented investors should Mentice achieve its sales growth targets and improve its profitability.